According to a July 19 Frontera Therapeutics press release provided to Becker’s, Frontera Therapeutics specializes in creating gene therapy candidates for various diseases. In addition to the fundraising announcement, Frontera Therapeutics confirmed that the FDA accepted the company’s application to begin human clinical trials for their gene therapy drug designed to treat rare genetic retinal disease.
The financing will create new manufacturing capabilities and investment in clinical development.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
